Teva Pharmaceutical Industries (NYSE:TEVA) Cut to “Buy” at StockNews.com

StockNews.com downgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a strong-buy rating to a buy rating in a research report sent to investors on Wednesday morning.

Several other analysts have also recently commented on the company. JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, UBS Group boosted their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $20.88.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $22.09 on Wednesday. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The stock has a market capitalization of $25.03 billion, a PE ratio of -25.99, a P/E/G ratio of 0.99 and a beta of 0.79. Teva Pharmaceutical Industries has a fifty-two week low of $10.34 and a fifty-two week high of $22.17. The company has a fifty day moving average of $17.79 and a two-hundred day moving average of $17.51.

Insider Activity at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.55% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. UMB Bank n.a. lifted its stake in Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after purchasing an additional 2,067 shares in the last quarter. Smithfield Trust Co raised its holdings in shares of Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after buying an additional 980 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in Teva Pharmaceutical Industries during the 3rd quarter worth about $50,000. Claro Advisors LLC purchased a new position in Teva Pharmaceutical Industries during the 3rd quarter valued at about $52,000. Finally, Mark Sheptoff Financial Planning LLC acquired a new position in Teva Pharmaceutical Industries in the 2nd quarter valued at about $57,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.